SOTIO

This #NationalInternDay we’re proud to recognize the talented students who have spent their summer at SOTIO through the Erasmus + program, including students from @imc_krems , @UofGlasgow , @VSCHT , and @science_charles . Their curiosity and eagerness to learn are part of what makes scientific research so rewarding. Thank you to our interns for all of your contributions, and to the SOTIO mentors who have helped support and inspire the next generation of scientists. #BiotechInterns #Internship #CompanyBuilding

Behind every advancement in sarcoma treatment research are the scientists and clinicians working to deepen our understanding of these challenging diseases. This #SarcomaAwarenessMonth, we’re revisiting Amy Jensen Smith’s reflections on how the complexity of sarcoma continues to shape her work in oncology and why advancing new treatment approaches remains so important for patients. Read the full byline below. #SarcomaInnovation #SarcomaResearch #DrugDiscovery

Today we announced the @EPOorg Boards of Appeal have upheld European Patent EP 3 444 271 B1, confirming intellectual property protection for SOT201, our next-generation PD-1-targeting immunocytokine. SOT201 is currently being evaluated in our Phase 1 VICTORIA-01 study in patients with advanced solid tumors. This decision reinforces the strength of SOT201 as it continues to show a high disease control rate, including objective responses in heavily pre-treated cancer patients. Read the full press release here: sotio.com/news-publicati… #Immunocytokine #PatentProtection #DrugDevelopment #ClinicalTrials

The @US_FDA has granted Fast Track Designation to SOT109, our next-generation antibody-drug conjugate targeting cadherin-17 (#CDH17) for the treatment of #ColorectalCancer (CRC). This designation recognizes the crucial need for new treatment options for patients with #CRC and the promise of SOT109 to extend targeted #ADC therapy to a substantially broader patient population. Read more in today’s press release: sotio.com/news-publicati… #FastTrackDesignation #FTD #ColorectalCancerInnovation #DrugDevelopment

Prague is earning recognition as one of Central Europe’s fastest-growing biotech hubs, and we’re excited to be part of the story. In the recent installment of @Labiotech_eu series spotlighting biotech ecosystems around the world, Prague is recognized for its world-class science, expanding innovation ecosystem, and growing global investment. The article highlights SOTIO as the largest Czech biotech company, alongside the many organizations helping drive the region’s momentum. We’re proud to contribute to Prague’s thriving life sciences community as we continue advancing next-generation targeted #cancertherapies that could benefit patients around the world. labiotech.eu/in-depth/pragu… #PragueBiotech #DrugDevelopment #OncologyInnovation

July is #SarcomaAwarenessMonth, dedicated to recognizing the impact of these rare and complex cancers. At SOTIO, we’re rapidly advancing our investigational antibody-drug conjugate SOT106 with plans to enter the clinic later this year. SOT106 recently received Orphan Drug Designation (#ODD) from the U.S. @FDA , underscoring both the urgent need for new sarcoma therapies and the potential of this program. #ADC #SarcomaInnovation #RareCancer #RareDisease #OncologyInnovation

Our investigational new drug (IND) application for SOT109 has been accepted by the @FDA for the treatment of colorectal cancer. SOT109 is an investigational antibody-drug conjugate (#ADC) targeting CDH17, which is expressed in over 90% of CRC cases. This milestone marks an important step forward in advancing a potential new targeted treatment option with best-in class properties for patients with CRC and other GI cancers. We look forward to sharing additional updates as we progress toward clinical development and key trial milestones. #INDAcceptance #DrugDevelopment #ClinicalTrials #OncologyResearch

Next week, SOTIO is heading to San Diego for the BIO International Convention 2026 (@IAmBiotech ). We’re looking forward to joining potential partners, life science investors, and industry peers to discuss the latest developments in #antibody-drug conjugates, including our #ADCs for treating solid tumors. Please reach out to Norbert Prenzel if you are attending and interested in connecting. #DrugDevelopment #BiotechPartnering #BIO2026 #oncology

Two wheels, many kilometers, and a shared commitment to sustainability! For the 9th year, SOTIO and SCTbio colleagues joined the ‘Bike To Work’ initiative. This year, 26 participants covered a total of 8,400 km, helping to reduce roughly 1,374 kg of CO2 emissions and supporting a more sustainable communing culture. Congratulations to this year’s top performers: Irena Kabátova (613.37 km) and Christian Frantz (933 km). Team Slowrider, consisting of Petra Svobodová, Adam Těhník, Martin Pávek, Aleš Slavíček and Jakub Lipovský, took first place with 2,335.82 km. Team Kološlapky followed with 2,084 km, and Team Kolohnáti with 1,601.5 km. Thanks to everyone who participated! #Sustainability #BikeToWork

Cancer Immunotherapy Month represents a meaningful moment to reflect on the progress being made in #cancer treatment and the continued need for innovation across modalities. Our work continues to span immuno-oncology and targeted therapies, including our next-generation PD-1 targeting #immunocytokine, SOT201, which is designed to reinvigorate exhausted T cells in tumors. #CancerImmunoTherapyMonth #ImmunoOncology #CancerResearch

New findings from the SOTIO research team, published in @tandfonline , highlight the potential of SOT201, a novel cis-acting PD-1/IL-15 mutein-based #immunocytokine, currently in development for the treatment of solid tumors. The study further demonstrates how targeted delivery of IL-15 signaling to PD-1+ T cells have the potential to help reinvigorate anti-tumor immune responses within the tumor microenvironment, supporting a differentiated approach to cytokine-based cancer immunotherapy. Read the report here: tandfonline.com/doi/full/10.10… #OncologyInnovation #Immunotherapy #CancerResearch

SOTIO will present research at the upcoming @EACRnews 2026 congress, exploring predictors of response to neoadjuvant anti-PD-1–based chemo-immunotherapy in non-small cell lung cancer (#NSCLC) using integrated spatial and immune profiling approaches. These findings highlight associations between pre-existing immune-active CD8+ T-cell populations, tertiary lymphoid structures, and treatment response, suggesting that baseline tumor immune characteristics may influence sensitivity to therapy. #EACR2026 #CancerResearch #DrugDevelopment

The @US_FDA has granted Orphan Drug Designation (ODD) to SOT106 for the treatment of osteosarcoma. SOT106 is a potential best-in-class antibody-drug conjugate (#ADC) for sarcoma, targeting LRRC15, a clinically validated target frequently expressed across multiple #sarcoma subtypes. This designation recognizes the significant unmet need for targeted therapies against this rare and aggressive #cancer. We look forward to bringing SOT106 into the clinic in the second half of this year. Read the full announcement here: sotio.com/news-publicati… #DrugDevelopment #SarcomaInnovation #OrphanDrug

Colorectal cancer (#CRC) is a significant global heath challenge, with many patients facing limited treatment options. According to @CancerResearch , colon cancer is now a leading cause of cancer-related death in young people. Next-generation #ADCs are emerging as a promising approach to treat this challenging cancer. SOT109, our ADC targeting CDH17, is approaching clinical studies as a novel treatment for CRC. Through programs such as SOT109, we’re advancing therapies with the potential to improve outcomes and expand options for patients living with #colorectalcancer. #OncologyResearch #ColorectalCancerInnovation #DrugDevelopment

We’re proud to see SOTIO’s research published in @NaturePortfolio Communications. The study highlights the potential of NKG2A inhibition to restore NK cell function and strengthen anti-tumor immune responses in #ovariancancer, further advancing the understanding of novel immunotherapy approaches. Congratulations to the researchers and collaborators involved in this important achievement! Check out more here: linkedin.com/posts/jitka-fu… #CancerImmunology #OncologyInnovation #DrugDevelopment

On #ClinicalTrialsDay, we join the global research community in celebrating the theme of “Research Rising,” which honors the progress, people, and purpose that drive clinical research forward. At SOTIO, we bring deep expertise in clinical development, working to translate scientific insights into meaningful treatment options for patients. We are advancing a pipeline of #ADCs focused on initiating clinical trials for cancers where patients continue to face significant unmet need. Together, we’re helping research rise to meet the needs of today and the promise of tomorrow. @ACRPDC #CTD2026 #ResearchRising #WeAllRiseTogether #DrugDevelopment #ADCs

SOTIO is heading to #ASCO26! We look forward to engaging with oncology researchers, industry leaders and investors about our #ADCs SOT106 and SOT109 entering the clinic later this year. If you’re attending, please reach out to Radek Spisek, CEO, Vivi Boura, CMO, and Martin Vodak, Business Development Senior Director. #ASCO26 #BiotechPartnering #DrugDiscovery

Bio€quity Europe 2026, organized by @BioCentury , @EBDgroup and Prague.bio, brought together an inspiring community of innovators, investors, and partners from across the global biotech ecosystem to our home of Prague. Our CEO, Radek Spisek, presented details on our growing pipeline and participated in a panel discussion, making it a valuable opportunity for SOTIO to connect with peers, discuss the latest industry developments, and showcase recent progress across our programs, including our next-gen #ADCs. Check out some snapshots from the event below. #BioEquityEurope #DrugDiscovery #OncologyInnovation